Heyndrickxia coagulans IDCC 1201 Alters Gut Microbiome and Metabolome in Patients with Functional Bowel Disorders
Nutrients · 29.07.2026 · 18 (15) · 2466
DOI: 10.3390/nu18152466 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 29.07.2026. Verfasst von Hyeon Ji Jeon und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, Republic of Korea. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Metabolome, Probiotics, Colonic Diseases, Functional. Die Arbeit nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry, National Research Foundation of Korea, Ildong Bioscience, Co., Ltd..
Abstract (Originalsprache)
Background/Objectives: Functional bowel disorders (FBDs) are chronic gastrointestinal conditions that substantially impair quality of life. This randomized, double-blind, placebo-controlled trial investigated the effects of Heyndrickxia coagulans IDCC 1201 (COA 1201) in adults with FBD.
Methods
Participants received COA 1201 or a placebo for 8 weeks, with outcomes assessed using the irritable bowel syndrome (IBS) Symptom Severity Score (IBS-SSS), IBS Quality of Life (IBS-QOL), and bowel activity measures. And Fecal microbiome and metabolomics were measured by 16S rRNA gene sequencing gas chromatography-mass spectrometry, respectively.
Results
Both groups showed improvement from baseline, but COA 1201 produced greater symptom relief, particularly in abdominal bloating, post-defecation discomfort, and the body image domain of IBS-QOL. Fecal microbiome profiling revealed modest changes in global diversity, yet taxa linked to saccharolytic activity and short-chain fatty acid production—including Ruminococcus bromii, Agathobacter rectalis, and Bifidobacterium—were enriched in participants receiving COA 1201, whereas Clostridium leptum increased in those receiving a placebo. Untargeted metabolomics demonstrated distinct metabolic signatures between groups, confirmed by supervised partial least squares discriminant analysis. Exploratory metabolites were identified using variable importance in projection scores (>1.5), statistical significance (p < 0.05), and absolute log2 fold change (>1). Alanine and proline emerged as time-dependent metabolites, while tryptophan, lactic acid, and phytosphingosine were specifically associated with COA 1201 treatment.
Conclusions
Collectively, these findings suggest that COA 1201 alleviates FBD symptoms by modulating the gut microbiome and metabolome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, Republic of Korea.
- ILDONG Bioscience Co., Ltd., 17 Poseunggongdan-ro, Poseung-eup, Pyeongtaek-si 17957, Republic of Korea.
- Department of Microbiology, College of Medicine, Inha University, Incheon 22212, Republic of Korea.
- Department of Microbiology, College of Medicine, Dongguk University, 123 Dongdae-ro, Gyeongju 38066, Republic of Korea.
- Division of Gastroenterology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 22212, Republic of Korea.
ORCID-Profile: Jin Seok Moon, Won Yeong Bang, Jungwoo Yang, Young Hoon Jung
Förderung
- Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry
- National Research Foundation of Korea
- Ildong Bioscience, Co., Ltd.
- Hanwoomul-Phagi Basic Research Program through the National Research Foundation of Korea (NRF) grant
- Korean government
Zitieren
APA
Jeon, H. J., Moon, J. S., Jeong, H. M., Bang, W. Y., Kim, H., Kim, D., Shin, M., Yang, J., Shin, J., & Jung, Y. H. (2026). Heyndrickxia coagulans IDCC 1201 Alters Gut Microbiome and Metabolome in Patients with Functional Bowel Disorders. Nutrients, 18(15), 2466. https://doi.org/10.3390/nu18152466
Vancouver
Jeon HJ, Moon JS, Jeong HM, Bang WY, Kim H, Kim D, et al. Heyndrickxia coagulans IDCC 1201 Alters Gut Microbiome and Metabolome in Patients with Functional Bowel Disorders. Nutrients. 2026;18(15):2466. doi:10.3390/nu18152466
BibTeX
@article{Jeon2026,
author = {Jeon, Hyeon Ji and Moon, Jin Seok and Jeong, Hye Min and Bang, Won Yeong and Kim, Hayoung and Kim, Donggyu and Shin, Minhye and Yang, Jungwoo and Shin, Jongbeom and Jung, Young Hoon},
title = {Heyndrickxia coagulans IDCC 1201 Alters Gut Microbiome and Metabolome in Patients with Functional Bowel Disorders},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {15},
pages = {2466},
doi = {10.3390/nu18152466}
}
EUVIMED